Type 2 Immunity Beyond Atopic Dermatitis
Unlock the clinical relevance of type 2 inflammation beyond atopic dermatitis. Dr Jeffrey Cohen explores cytokine pathways, JAK-STAT signaling, and pivotal dupilumab trials for prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid, including highlights from the PRIME, LIBERTY-CSU, and BP-ADEPT studies.
Jeffrey M. Cohen, MD, is a board-certified medical dermatologist, assistant professor, and the director of the Interdisciplinary Psoriasis Treatment Program of department of dermatology and department of biomedical informatics and data science at the Yale School of Medicine in Branford, CT.
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the Dermatology Learning Network or HMP Global, their employees, and affiliates.
Related Content
Where Dermatology APPs Learn, Lead, and Level Up.
The Derm APP is dedicated to educating and informing advanced practice providers on clinical topics and practical issues to support the profession and improve the quality of patient care across the spectrum of dermatology.
The Derm APP is designed for advanced practice providers who specialize in dermatology to further their education and increase their knowledge to achieve better patient outcomes. Explore cutting-edge research, innovative treatment options, and new therapeutic methods while remaining focused on the fundamental principles and terminology associated with dermatology. Engage year-round with The Derm APP to access clinical insights, interactive features, research news updates, accredited continuing-education programs, and more.
